8 results

Avara broke even between 2016 and 2018, but since then has been loss-making, counsel says.

The High Court has made orders winding up a Co Clare-based pharmaceutical company employing more than 110 people. Avara Shannon Pharmaceutical Servi(...)

The Syndesi Therapeutics drug is directly targeting dementia, the core symptom of Alzheimer’s disease. Photograph:  John Stillwell/PA

Irish venture capital group Fountain Healthcare has invested in a Belgian start-up that is investigating a dementia therapy. The company, Syndesi The(...)

Kingspan chief executive Gene Murtagh:  company closed up 0.3 per cent at €21.86   on Iseq yesterday after stockbroker Davy issued an upbeat note. Photograph: Cyril Byrne

European shares rose briefly yesterday before ending the day level. Many markets, including Austria, Greece, Italy and Poland, were closed for a holi(...)

GV Prasad, chief executive of Dr Reddy’s Laboratories. India is the company’s second largest market after the US. Photograph: Prashanth Vishwanathan/Bloomberg

Dr Reddy’s Laboratories, India’s second-largest pharmaceutical company, expects domestic sales to grow nearly 20 per cent this financial year, helped (...)

Bank of Ireland climbed 2.21 per cent to 32.4 cents. Volumes were decent, with 292 million shares changing hands

Markets bounced back from an earlier slide as hydrocarbon and mining stocks regained some momentum following increases in oil and metals prices.Hopes(...)

Sanofi chief executive Chris Viehbacher said China’s ministry of industry and commerce had come to the company’s office in Shenyang, but the reason for the visit was not yet clear.

Chinese officials this week visited a regional office of Sanofi, the French pharmaceutical company, in the latest expansion of investigations of weste(...)

Andrew Witty, GlaxoSmithKline Plc chief executive officer: he will hope his investors are concentrating on the numbers when he unveils the FTSE 100 giant’s second-quarter financial results at midday today.

GlaxoSmithKline chief executive Sir Andrew Witty will hope his investors are concentrating on the numbers when he unveils the FTSE 100 giant’s second-(...)

Those who haven’t been to LA disguise their aversion to it with a line of harmless rhetorical questioning, usually concerning the car. Isn’t it ver(...)